Danish drugmaker Nycomed has completed its previously-announced $346.0 million acquisition of US specialty and generics drugmaker Bradley Pharmaceuticals (Marketletter November 5, 2007). With this, Nycomed will expand the line of dermatological products currently offered through its PharmaDerm Division and thereby increase market coverage and drive future growth. Combined with Nycomed's Fougera Division, total annualized sales will be $450.0 million, making Nycomed a leader in the US dermatology market, the firm claims.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze